Lonza Biologics Inc.

Innovations in obesity, ovarian cancer vaccines, Alzheimer’s, and mental health drugs are transforming healthcare, with UK tech stocks and biotech sectors offering untapped investment opportunities. Key players include Intra-Cellular Therapies, Supernus Pharmaceuticals, and specialist providers like Bioventix and Diaceutics. Funds like Comgest Growth Europe ex UK and Polar Capital Global Healthcare Trust offer diversified healthcare exposure.

Lonza completed the first GMP product batch at its next-gen mammalian manufacturing facility in Portsmouth, NH, addressing market demand for small- to mid-scale biologics. The facility offers flexibility, reduced costs, and supports high-titer processes, complementing existing commercial manufacturing scales.

Lonza completes first GMP batch at its next-gen mammalian manufacturing facility in Portsmouth, enabling support for small- to mid-scale biologics and high-titer processes, addressing market demand and product lifecycle needs.

The global single-use bioreactors market is projected to reach USD 9.1 billion by 2029 from USD 4.4 billion in 2024, at a CAGR of 15.4%. The pharmaceutical & biotechnology companies segment dominated the market in 2023, driven by rising R&D initiatives and increased production of biologics and biosimilars. The US continues to lead the market, supported by active participation in biologics and biosimilars development and the advantages of single-use bioreactors.

Lonza completed the first GMP product batch from its next-gen mammalian facility in Portsmouth, NH, offering flexibility, reduced costs, and reliable market access for various molecule types, complementing existing commercial manufacturing scales.

The global halal empty capsules market is projected to grow from USD 1.28 billion in 2024 to USD 2.16 billion by 2034, driven by increasing demand for halal-certified products and plant-based capsules. North America dominated the market in 2023, while Asia Pacific is expected to grow fastest. The gelatin segment led in 2023, but non-gelatin is projected to grow significantly. The pharmaceutical industry is the largest application segment, with the nutraceutical segment expected to grow rapidly. AI is enhancing drug manufacturing processes, and rising demand for dietary supplements and generic drugs is boosting market growth. Challenges include the lack of halal-certified raw materials and the costly certification process.

The Biotechnology Reagents Market is projected to reach USD 1.07 billion by 2031, driven by rising R&D investments and technological advancements. Key players include Abbott, Agilent Technologies, Danaher, and Bio-Rad Laboratories. The market is expected to grow at a CAGR of 12.20% from 2022 to 2029, with North America leading in adoption.

Lonza expands bioconjugation capabilities in Switzerland with two new manufacturing suites, doubling multipurpose capacity for bioconjugates. The 2,000m² expansion aims to meet market demand, creating 200 jobs and operational by 2028. The investment follows a recent customer-dedicated expansion in Visp (CH).

Lonza expands bioconjugation facility in Visp with two 1,200 L multipurpose suites, doubling capacity for ADCs and bioconjugates, expected to create 200 jobs by 2028. The suites, designed for complex processes, also follow sustainability standards reducing carbon footprint and waste by up to 90%.

Lonza to invest in additional bioconjugation capabilities in Visp, Switzerland, adding two 1,200 L manufacturing suites, doubling multipurpose capacity for bioconjugates, and generating 200 new jobs by 2028. The expansion supports early phase clinical development to commercial supply, includes drug product filling, and follows sustainability design standards.